Loading
Ascendis Pharma A/S Stock: price and insider trades · United States
US·Mcap US$14.9B
1 insider bought €427k of shares over the last 90 days, the latest filed 18 Aug 2026.
Ascendis Pharma A/S: what insiders have been doing
Ascendis Pharma A/S is a listed company. Filings by its managers are published through SEC (Form 4). 6 insiders have disclosed 14 filings since 18 October 2025.
Purchases and sales both appear in the filings: 9 purchases (2 insiders, €672k) and 3 sales (3 insiders, €4.7M). The net balance comes to €4.0M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 finance chief and 1 senior executive. Jensen Flemming Steen filed the largest sale, €3.9M, on 12 May 2026.
In all, 5 purchases were made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 18 August 2026, which is 61 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
With 14 filings in twelve months, the company is quieter than the median of 19 filings across the 5,808 companies we follow on the same exchange. Our records for Ascendis Pharma A/S go back to 2026, with 9 purchases and 3 sales on the open market in total.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€671,606
9 ops. · all time
Sell Volume
€5M
3 ops. · all time
Who traded when
BuySaleJean Jacques Bienaime7 buys
Scott Thomas Smith2 buys
Flemming Steen Jensen1 sale
Lars Holtug1 sale
Mads Bodenhoff1 sale
Since the insiders bought
- -12.6%Entry US$259.62 · Close 14 Oct 2026 US$227.00
- +20.0%Entry US$216.79 · Close at T+90 US$260.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ascendis Pharma A/S Strong Buy (bullish), based on 20 analysts. Average price target: US$308.15.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,853 of 24,148 companies
49.8
score / 100
Value33
Quality66
FCF yld0.3%
Earn yld-1.5%
EV/EBITDA·
ROE119%
Gross mgn87%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$227.00
Analyst consensus
20 analystsStrong buy
US$262.34Target US$308.15(+36%)US$350.03
Income statement
RevenueUS$720.1M
Gross profitUS$625.2M87% margin
EBITDA-US$114.3M-16% margin
Net income-US$228M70.8% margin
Valuation
PER (trailing)17.4x
PER (forward)23.6x
P/Book9.2x
Balance sheet & cash
Market capUS$14.9B
Total debtUS$871.8M
Free Cash FlowUS$45.4M
Debt / Equity31%
Profitability & ownership
ROE118.8%
ROA9.6%
% insiders0.8%
% institutions103.0%
Last declaration on 9 September 2026
Declarations14 total
3,000 shares@ US$110.000.0021% mcap16.9% of flowOrdinary SharesSEC:0001610717-26-000409:0
3,000 shares@ US$270.190.0052% mcap41.5% of flowOrdinary SharesSEC:0001610717-26-000409:1
3,000 shares@ US$270.18760.0052% mcap41.5% of flowAmerican Depositary SharesSEC144:0001964306-26-000432
236 shares@ US$264.12960.0004% mcap100.0% of flowOrdinary SharesSEC:0001610717-26-000395:0
1,100 shares@ US$245.850.0018% mcap38.8% of flowOrdinary SharesSEC:0001610717-26-000360:0
Canonical exit: 12 Nov 2026 (T+90)
900 shares@ US$246.910.0014% mcap31.8% of flowOrdinary SharesSEC:0001610717-26-000360:1
Canonical exit: 12 Nov 2026 (T+90)
100 shares@ US$219.0028.2% of flowOrdinary SharesSEC:0001610717-26-000179:0
Canonical exit: 31 Aug 2026 (T+90)
250 shares@ US$223.3271.8% of flowOrdinary SharesSEC:0001610717-26-000176:0
Canonical exit: 27 Aug 2026 (T+90)
200 shares@ US$223.766.4% of flowOrdinary SharesSEC:0001610717-26-000177:0
Canonical exit: 27 Aug 2026 (T+90)
200 shares@ US$222.306.3% of flowOrdinary SharesSEC:0001610717-26-000177:1
Canonical exit: 27 Aug 2026 (T+90)
100 shares@ US$223.503.2% of flowOrdinary SharesSEC:0001610717-26-000177:2
Canonical exit: 27 Aug 2026 (T+90)
200 shares@ US$236.2356.7% of flowOrdinary SharesSEC:0001610717-26-000161:0
Canonical exit: 24 Aug 2026 (T+90)
200 shares@ US$239.36756.8% of flowOrdinary SharesSEC:0001610717-26-000161:1
Canonical exit: 24 Aug 2026 (T+90)
19,460 shares@ US$238.4903100.0% of flowOrdinary SharesSEC:0001610717-26-000159:0
14 of 14 declarations
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative treatments for endocrine diseases and other medical conditions. It utilizes its drug technology platform to create peptide-based therapies.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
